Drugs / OCF001
last change Jun 2026 re-read 3 minutes ago

OCF001

Developed for
vulvovaginal candidiasis
Investigated by
Sano Chemicals Inc

Trials 1

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT07521137 Jun → Dec 2026 expected vulvovaginal candidiasis Sano Chemicals Inc Recruiting No outcome recorded

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as OCF001 ClinicalTrials.gov intervention name — accepted as the source's own label NCT07521137 ↗